Financial Data and Key Metrics - The company crossed the 10,000 case mark for the year, compared to close to 8,000 in 2023 [7] - Q3 pathology revenues reached $4.5 million, an 18% increase from Q2 [9] - Q3 Products division revenues increased by 13% over Q2, reaching $680,000 [13] - Cash burn reduced by 75% from approximately $1 million in Q3 2023 to $226,000 in Q3 2024 [19] Business Line Performance - Pathology division exceeded breakeven for the second consecutive quarter, with a goal to reach a $20 million run rate [9] - Products division is progressing towards breakeven, with three key customers in onboarding stages expected to significantly impact performance [13] - Products division is expected to become the main growth engine due to recurring revenue, customer retention, and higher margins [14][15] Market and Strategic Direction - The company aims to achieve breakeven in 2024, avoiding dilutive capital raises and focusing on organic growth [8] - Pathology division serves as a self-sustained cost-free R&D platform, supporting future product development [10] - The company plans to leverage distribution channels for product sales, increasing revenue share from distributors [17][18] Management Commentary on Environment and Outlook - Management is confident in achieving financial independence and building cash reserves through organic growth [20][21] - The company plans to enhance investor education and visibility through investor conferences, analyst coverage, and consistent performance [25][26] - Management anticipates ending the year strong and entering the next year with even stronger performance [27] Other Important Information - The company’s sales team consists of five members in the pathology division and three in the products division, with potential hiring for additional stability [11][16] - The majority of revenues are currently from direct sales, but a gradual shift towards distributor-generated revenue is expected [17] Q&A Session - No specific questions or answers were provided in the transcript [31]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-36439 PRECIPIO, INC. (Exact name of registrant as specified in its charter) Delaware 91-17893 ...

NEW HAVEN, Conn., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the launch of a new version of its Bloodhound MPN (Myeloproliferative Neoplasm) panel that is now able to distinguish between CALR type 1 and type 2 mutations. The CALR mutation data plays a critical role in disease prognosis and therapeutic decision-making. This differentiation aligns with the latest National Comprehensive Cancer Network (NCCN) guidelines released in August of th ...

NEW HAVEN, Conn., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the Company's repricing of a portion of its employee stock options to ensure their effectiveness as a retention tool for valuable employees. Management is confident that the practical, strategic, and economic benefit to shareholders will ultimately be positive. Retaining valuable employees in an extremely competitive industry is key to ensuring the company's continued growth and ...

NEW HAVEN, Conn., July 25, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces that its unaudited non-GAAP Cash Burn/Generated from Operations (CBFO) for Q2-2024 was $0.3M of cash generated for the quarter. It is important to note that a small contributing factor to the cash increase was the incoming cash collections that were expected in Q1, but were delayed and received in Q2 due to the impact of the Change Healthcare hack, as previously described. With ca ...

Pathology Division revenue in June reached its breakeven point, and the company anticipates continued growth in the next few months. We expect this division's revenues will reach more than $1.5 million per month by year end, well above its breakeven goals. About Precipio Forward-Looking Statements NEW HAVEN, Conn., July 17, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that for Q2-2024, its unaudited revenues have grown from $3.4M in Q1- 2024 to $4.4M ...

no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by the federal securities laws. Precipio shareholders as of the April 19, 2024 record date for the Annual Meeting are invited to attend the virtual Annual Meeting by visiting www.virtualshareholdermeeting.com/PRPO2024. About Precipio Forward-Looking Statements NEW HAVEN, Conn., June 13, 2024 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipi ...

During this process, we've realized that there are quite a few shareholders who didn't know whether their shares were voted on or not. You can accomplish this in one of three easy ways that will take no more than 60 seconds: The record date for determining shareholders eligible to vote at the Annual Meeting will remain the close of business on April 19, 2024. Shareholders who have already submitted a proxy do not need to vote again for the reconvened Annual Meeting, as the proxies submitted will remain vali ...

NEW HAVEN, Conn., June 12, 2024 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) is requesting that shareholders instruct their brokers to vote their shares immediately today no later than 11pm Eastern Time. In order to ensure that there is a quorum required for the shareholders' meeting that is scheduled to take place tomorrow June 13, 2024 at 10 a.m. Eastern Time. At the time of this press release, approximately 44% of shares have been voted. For the com ...

In September of 2023, Precipio's pathology division exceeded its breakeven point of $15M annualized revenue run rate, resulting in a Q4 cash burn of less than $100K for the quarter. In the following quarter, as previously discussed, due to several operational issues, revenue declined below that point. 2. Change Healthcare hacking & cash impact This rule creates two options to comply: The FDA rule has stipulated that any tests that a lab was operating before the ruling on May 2023 are "grandfathered" into ap ...